Drugs / FBTA05
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01138579 | Aug 2010 → May 2015 | disease related to hematopoietic stem cell transplant, leukemia | Technical University of Munich | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FBTA05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01138579 ↗ |
| Known as | Bi20 | “Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody” PMID 23815981 ↗ Jul 2013 |
| Target | MS4A1 | “B-lymphocyte antigen CD20 cross-linking agent” CHEMBL2109351 ↗ |